Emerging drugs for non-alcoholic steatohepatitis.

@article{Tomeno2013EmergingDF,
  title={Emerging drugs for non-alcoholic steatohepatitis.},
  author={Wataru Tomeno and Masato Yoneda and Kento Imajo and Yuji Ogawa and Takaomi Kessoku and Satoru Saito and Yuichiro Eguchi and Atsushi Nakajima},
  journal={Expert opinion on emerging drugs},
  year={2013},
  volume={18 3},
  pages={279-90}
}
INTRODUCTION The prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is increasing along with the worldwide epidemic of obesity and their strong association with metabolic syndrome. Currently existing pharmacological therapies include anti-oxidants, insulin-sensitizing agents, lipid-lowering drugs and cytoprotective agents, but there is a lack of consensus regarding the most effective and appropriate pharmacologic therapies for NASH. Clinical trials… CONTINUE READING